From Market Authorization to Value Architecture: Why AI Diagnostics Are Entering a New Era
For years, AI diagnostics have been evaluated primarily through the lens of algorithm performance, market authorization and reimbursement planning. Increasingly, however, value is no longer created by the algorithm alone. It is created by the ability to integrate AI into a reproducible diagnostic ecosystem that demonstrates clinical utility, economic value, and sustainable reimbursement. CMS’s proposed […]
One Year of SolarisRTC Europe: What We Learned
One year ago, SolarisRTC Europe was established and this anniversary is a perfect moment to reflect on the connections between European and US healthcare ecosystems. Over the past year, working across both regions has provided a unique vantage point into how digital health innovations are implemented in practice. One observation has become increasingly clear: Digital […]
When Alignment Holds, Execution Follows
Part III of a Trilogy on Alignment in Digital Health The first two posts in this trilogy explored a persistent reality: innovation in digital health rarely stalls because of science. It stalls when alignment is missing. This final post focuses on what changes when alignment holds. Across digital health, progress depends on the ability of […]
Three years of SolarisRTC
And I couldn’t have asked for a better way to reflect on this journey than celebrating it at the MedTech event here in Maryland. It felt fitting. Just coming out of USCAP, where the conversations grounded us in the current state of digital pathology, AI, and diagnostics, what is working, where we are progressing, and […]
When Alignment Becomes a Leadership Discipline
Part II of a Trilogy on Alignment in Digital Health In my December reflection: A Year End Reflection on Innovation, I argued that most delays in pharma and diagnostics are not scientific, but structural. Driven by misalignment across decision lenses and ecosystem forces. This second post is a deliberate continuation. If misalignment is the hidden […]
A Year End Reflection on Innovation
As the year draws to a close, this feels like the right moment to pause, not to push harder, but to reflect. In pharma and diagnostics, delays rarely come from science. They come from misalignment. Pharma evaluates progress through five decision lenses that shape strategy, investment, and risk: discovery and lead optimization, pre-clinical and clinical development, regulatory strategy, market access, and commercialization. These […]
Innovation Is Growing Old. The Existing Model Isn’t Built to Carry It. (Blog 3 of 3)
This is the final post in a three part series exploring diagnostics innovation, digital pathology, and the future of infrastructure in digital health driven care: Innovation is not failing. But it’s aging in place, unused, unintegrated, and underleveraged. Digital pathology works, not only for diagnosis, but as the foundation for computational biomarkers. AI is maturing. Biomarkers […]
SolarisRTC Europe: From Vision to Reality On June 11, 2025, SolarisRTC officially became established in Europe. Today, a little over three months later, I pause with gratitude. I am thankful for the many experts I have been working with those who shared knowledge, perspective, and trust to make this step possible. And I am proud of […]
How AI & Digital Pathology Should be Advancing Rare Cancer Diagnosis (Blog 2 of 3)
Precision tools for complex oncology challenges Picking up where we left off (see Accelerating Rare Disease Diagnosis): our digital pathology journey continues, this time focused on rare cancers. These are often underrepresented, underdiagnosed, and underserved, despite their significant burden. Globally, rare cancers account for approximately 26.7% of all new cancer cases and 30% of cancer related deaths (GLOBOCAN 2022). In […]
The Role of AI in Accelerating Rare Disease Diagnosis (Blog 1 of 3)
AI in rare disease diagnosis: Advancing Precision and Timely Access with Digital Pathology When talking with a friend about rare cancers and how the system is not serving those patients, I thought, not only do we have rare cancers, we have many rare diseases. So, I started my research: “Over 300 million people worldwide live with […]